

LYNX THERAPEUTICS INC

Form 8-K

November 13, 2003

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 13, 2003

Date of Filing: November 13, 2003

**Lynx Therapeutics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-22570**

(Commission File No.)

**94-3161073**

(IRS Employer Identification No.)

**25861 Industrial Blvd.**

**Hayward, California 94545**

(Address of Principal Executive Offices and Zip Code)

Registrant's telephone number, including area code: **(510) 670-9300**

---

**TABLE OF CONTENTS**

Item 12. Results of Operations and Financial Condition

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

**Item 12. Results of Operations and Financial Condition**

On November 13, 2003, Lynx Therapeutics, Inc. issued a press release announcing financial results for the quarter ended September 30, 2003. A copy of such press release, entitled "Lynx Announces its Financial Results for Third Quarter 2003," is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Lynx Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**LYNX THERAPEUTICS, INC.**

Dated: November 13, 2003

By: /s/ Edward C. Albini

---

Edward C. Albini  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

**Table of Contents**

**INDEX TO EXHIBITS**

99.1 Press release entitled Lynx Announces its Financial Results for Third Quarter 2003, dated November 13, 2003.